Together, these results provide evidence that IMiD-acquired resistance in MM is, next to genetic mutations in CRBN, also driven by epigenetic mechanisms and that one or more EMAs together with IMiDs can restore sensitivity. Here, CRBN is linked to Miyoshi myopathy.